| Bioactivity | Varlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1]. |
| Target | IC50: 7 nM (HER1), 2 nM (HER2), 4 nM (HER4) |
| Invitro | 在使用过度表达 EGFR (A431) 或 ErbB-2 (BT474) 的肿瘤细胞进行的基于细胞的测定中，Varlitinib tosylate (ARRY-334543) 有效抑制底物磷酸化。 Varlitinib tosylate 被证明对 EGFR/ErbB-2 具有高度选择性，并且在针对一组 104 种激酶进行筛选时未显示任何显着活性[2]。 |
| In Vivo | Varlitinib tosylate 可有效抑制肿瘤生长，在每天两次 100 mg/kg 的剂量下可使肿瘤完全消退。Varlitinib tosylate 处理五天后，HER1-3、RAS/RAF/MEK/MAPK、p70S6K、S6 核糖体、4EBP1、Cdk-2、Cdc-2 和视网膜母细胞瘤的磷酸化受到强烈抑制。Varlitinib tosylate 处理导致生存素显着减少，同时 Caspase 3 裂解产物增加[1]。在小鼠异种移植模型中，Varlitinib tosylate（25、50、100 mg/kg）通过口服给药，每天两次，持续 21 天，在 A431 衍生肿瘤中表现出显着的剂量相关肿瘤生长抑制[2]。 |
| Name | Varlitinib tosylate |
| CAS | 1146629-86-8 |
| Formula | C36H35ClN6O8S3 |
| Molar Mass | 811.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hsieh C, et al. Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models. Journal of Clinical Oncology 34, no. 15_suppl [2]. Miknis G, et al. ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2.Proc Amer Assoc Cancer Res, Volume 46, 2005 |
Varlitinib tosylate
CAS: 1146629-86-8 F: C36H35ClN6O8S3 W: 811.35
Varlitinib (ASLAN001) tosylate is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for H
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.